Clinical Trial

A Clinical Study of GK02 in Malignant Ascites

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
A single-arm, single-center, open-label clinical study comprising three cohorts, evaluating the safety, preliminary efficacy, and pharmacokinetic/ pharmacodynamic (PK/PD) characteristics of autologous tumor-reactive T cells (GK02) derived from malignant ascites caused by advanced solid tumors. The trial initially plans to enroll 9 subjects with malignant ascites caused by advanced solid tumors.
Trial Details
NCT Number NCT07378436
Lead Sponsor Beijing Geekgene Technology Co., LTD
Collaborators: Beijing GoBroad Hospital
Conditions Malignant Ascites Caused by Advanced Solid Tumors
Enrollment 9 participants
Start Date 2025-09-16
Primary Completion 2026-12-17 (estimated)
Study Completion 2027-12-17 (estimated)
Updated on ClinicalTrials.gov 2026-01-30